Tibet Aim Pharm. (SZ:002826)2025-05-14 10:24Group 1: Company Performance and Strategy - The company has adjusted its strategic planning to focus on self-produced products, maintaining the performance growth of its core product, Miglitol tablets, which has seen an increasing proportion of total revenue [2][5]. - The revenue from third-party cooperative products has gradually declined, leading to the termination of such collaborations [2]. - The company aims to explore the clinical value of existing products and plans to launch some dormant products, enhancing its product system through various means [2][5]. Group 2: Financial Management and Investor Relations - The company reported a profit increase for 2024, primarily due to the absence of a goodwill impairment charge of CNY 19.8 million that was recorded in 2023 [5]. - The board of directors has proposed a profit distribution plan for 2024, which will be submitted for approval at the annual shareholders' meeting [3]. - The company emphasizes the importance of rational investment and risk awareness due to the influence of macroeconomic factors on stock prices [3][6]. Group 3: Shareholder Concerns and Corporate Governance - The reduction of shares by a board member is attributed to personal financial needs, with no intention of exiting the board [1][2]. - The company has no current plans for a private placement, despite having idle funds for financial management [3]. - The management reassures investors of their confidence in the company's future development and industry prospects [3][5]. Group 4: Product Development and Market Position - The company is focused on developing core products for chronic diseases and women's health, with an emphasis on maintaining stable operations [4][5]. - The core product, Miglitol tablets, is highlighted as a key focus area for the company [7]. - The company is exploring new product introductions and partnerships to enhance its market position [5][6].